scholarly journals Cervical Cancer Screening of Women Living with HIV Infection: A Must in the Era of Antiretroviral Therapy

2007 ◽  
Vol 45 (4) ◽  
pp. 510-513 ◽  
Author(s):  
S. Franceschi ◽  
H. Jaffe
Keyword(s):  
Cervical Cancer ◽  
Cancer Screening ◽  
Antiretroviral Therapy ◽  
Hiv Infection ◽  
Cervical Cancer Screening ◽  
Women Living With Hiv ◽  
Living With Hiv

scholarly journals Impact of cervicitis on performance of cervical cancer screening using HRHPV testing and visual evaluation in women living with HIV in Botswana

2020 ◽  
Vol 151 (1) ◽  
pp. 144-146
Author(s):  
Helena Painter ◽  
Adrienne Erlinger ◽  
Boikhutso Simon ◽  
Chelsea Morroni ◽  
Doreen Ramogola‐Masire ◽  
...  
Keyword(s):  
Cervical Cancer ◽  
Cancer Screening ◽  
Cervical Cancer Screening ◽  
Visual Evaluation ◽  
Women Living With Hiv ◽  
Living With Hiv

scholarly journals Cost-Effectiveness of Cervical Cancer Screening in Women Living With HIV in South Africa

2018 ◽  
Vol 79 (2) ◽  
pp. 195-205 ◽  
Author(s):  
Nicole G. Campos ◽  
Naomi Lince-Deroche ◽  
Carla J. Chibwesha ◽  
Cynthia Firnhaber ◽  
Jennifer S. Smith ◽  
...  
Keyword(s):  
South Africa ◽  
Cervical Cancer ◽  
Cost Effectiveness ◽  
Cancer Screening ◽  
Cervical Cancer Screening ◽  
Women Living With Hiv ◽  
Living With Hiv

scholarly journals Comprehensive knowledge and uptake of cervical cancer screening is low among women living with HIV/AIDS in Northwest Ethiopia

2017 ◽  
Vol 4 (1) ◽  
Author(s):  
Daniel Asfaw Erku ◽  
Adeladlew Kassie Netere ◽  
Amanual Getnet Mersha ◽  
Sileshi Ayele Abebe ◽  
Abebe Basazn Mekuria ◽  
...  
Keyword(s):  
Cervical Cancer ◽  
Cancer Screening ◽  
Cervical Cancer Screening ◽  
Northwest Ethiopia ◽  
Women Living With Hiv ◽  
Comprehensive Knowledge ◽  
Living With Hiv ◽  
Hiv Aids

scholarly journals Costs and cost-effectiveness of cervical cancer screening strategies in women living with HIV in Burkina Faso: The HPV in Africa Research Partnership (HARP) study

PLoS ONE ◽  
2021 ◽  
Vol 16 (3) ◽  
pp. e0248832
Author(s):  
Angela Devine ◽  
Alice Vahanian ◽  
Bernard Sawadogo ◽  
Souleymane Zan ◽  
Fadima Yaya Bocoum ◽  
...  
Keyword(s):  
Cervical Cancer ◽  
Cancer Screening ◽  
Burkina Faso ◽  
Cervical Cancer Screening ◽  
Visual Inspection ◽  
Screening Tests ◽  
Research Partnership ◽  
Women Living With Hiv ◽  
Screening Strategies ◽  
Living With Hiv

Introduction This study estimated the costs and incremental cost per case detected of screening strategies for high-grade cervical intraepithelial neoplasia (CIN2+) in women living with HIV (WLHIV) attending HIV clinics in Burkina Faso. Methods The direct healthcare provider costs of screening tests (visual inspection with acetic acid (VIA), VIA combined visual inspection with Lugol’s iodine (VIA/VILI), cytology and a rapid HPV DNA test (careHPV)) and confirmatory tests (colposcopy, directed biopsy and systematic four-quadrant (4Q) biopsy) were collected alongside the HPV in Africa Research Partnership (HARP) study. A model was developed for a hypothetical cohort of 1000 WLHIV using data on CIN2+ prevalence and the sensitivity of the screening tests. Costs are reported in USD (2019). Results The study enrolled 554 WLHIV with median age 36 years (inter-quartile range, 31–41) and CIN2+ prevalence of 5.8%. The average cost per screening test ranged from US$3.2 for VIA to US$24.8 for cytology. Compared to VIA alone, the incremental cost per CIN2+ case detected was US$48 for VIA/VILI and US$814 for careHPV. Despite higher costs, careHPV was more sensitive for CIN2+ cases detected compared to VIA/VILI (97% and 56%, respectively). The cost of colposcopy was US$6.6 per person while directed biopsy was US$33.0 and 4Q biopsy was US$48.0. Conclusion Depending on the willingness to pay for the detection of a case of cervical cancer, decision makers in Burkina Faso can consider a variety of cervical cancer screening strategies for WLHIV. While careHPV is more costly, it has the potential to be cost-effective depending on the willingness to pay threshold. Future research should explore the lifetime costs and benefits of cervical cancer screening to enable comparisons with interventions for other diseases.

Sign in / Sign up

Export Citation Format

Share Document